tbuckley/cabot-search huggingface dataset:
Arthur Lee (the Wasp) and the Secret Diplomacy of the American Revolution
Authors: William S. Curran
Journal: New England Journal of Medicine (1961)

IN The Life of Samuel Johnson the famous episode occurs in which the great lexicographer is tricked by Boswell into attending a dinner at Dilly's, a well known bookseller's house. Also invited were several people notably uncongenial to Johnson. One was a stranger whom he did not recognize, and Boswell heard him whisper to Mr. Duly, "'Who is that gentleman, Sir?' — 'Mr. Arthur Lee' — JOHNSON — 'Too, too, too' (under his breath which was one of his habitual mutterings). Mr. Arthur Lee could not but be very obnoxious to Johnson, for he was not only a patriot, . . .
Regular review: somatostatin.
Authors: S A Jenkins, J N Baxter, S Ellenbogen, R Shields
Journal: BMJ (1987)

peak plasma insulin value was reached 15 minutes after glucose injection.These findings lead us to conclude that intra- venous administration of hypertonic solutions such as glucose 40%, but probably also radio- graphic contrast media, may cause a fall of blood pressure in the elderly, probably through direct vasodilatation.Secondly, the endogenous insulin response to glucose 40% given intravenously elicited no effect on blood pressure in the elderly.
The Physiology of the Thymus Gland
Authors: G. Keynes
Journal: BMJ (1954)

Thomas Young, whom we are commemorating, entered on his medical career in 1793 at the age of 20 as a student at my own hospital of St. Bartholomew.He published his first scientific paper on the accommo- dating power of the eye very soon afterwards, and in the next year, 1794, was elected a Fellow of the Royal Society.It may be doubted whether it would now be possible for any medical student, however brilliant, to achieve an F.R.S. in his first year at hospital.The Royal Society, however, took a chance on Thomas Young, and seldom has their choice been more fully justified in the event.I need not enlarge on Young's outstanding achievements in his work on the physiology and physics of the eye.Much of his work has stood the test of time, and his teaching is current at the present day.He was, moreover, a man of extraordinary versatility, so that he became eminent as physiologist, mathematician, physicist, physician to St. George's Hospital, and, un- expectedly, Egyptologist.He was, indeed, the chief interpreter of the Rosetta Stone.He also made observa- tions on the habits of spiders.All these positive achievements contrast richly with the comparative poverty of the theme I am proposing to unfold under the aegis of Young's name.If a student were asked to-day, "What is known of the physiology of the thymus gland," he would probably return the perfectly reasonable answer, " Well, practically nothing."So it is a sort of spider's web story that I shall have to spin, full of holes and very shaky.Fortunately the term " physiology " does not compel nowadays confine- ment within a single scientific cell.No compartments are now watertight, and none will mind, I hope, if I touch on matters that are anatomical, clinical, pathological, and historical.I have even seen the term " physio-pathology " used recently in a reputable journal, and this gives me a little more confidence.The Harveian Orator for 1953 has also given en- couragement-" The advances in physiology," Dr. Graham said, " have been made not only by those who work in the physiological laboratories but also by the whole army of clinicians, chemists, biochemists, bio- logists, physicists, anatomists, pharmacologists, and pathologists who have contributed their experiences."Why did not he add " surgeons " to his list?But it is not unusual to find that surgeons are regarded merely as carpenters or plumbers, and not very intelligent ones either.Call us " craftsmen " and we shall not mind.
CHEILITIS GLANDULARIS HETEROTOPIC SALIVARY GLANDS AND SQUAMOUS CELL CARCINOMA OF THE LIP.
Authors: R. MICHAŁOWSKI
Journal: British Journal of Dermatology (1962)

Journal Article CHEILITIS GLANDULARIS HETEROTOPIC SALIVARY GLANDS AND SQUAMOUS CELL CARCINOMA OF THE LIP. Get access R. MICHAŁOWSKI, M.D., M.Ph. R. MICHAŁOWSKI, M.D., M.Ph. Warsaw Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 74, Issue 12, 1 December 1962, Pages 445–449, https://doi.org/10.1111/j.1365-2133.1962.tb13443.x Published: 01 December 1962
The detection of silent ischemia: cautions and precautions.
Authors: D S Berman, A Rozanski, S B Knoebel
Journal: Circulation (1987)

THERE IS NOW convincing evidence that myocardial ischemia may occur in the absence of symptoms.'This phenomenon, which has acquired the label "silent ischemia," is receiving considerable attention as a factor with potential prognostic significance in the management of coronary artery disease.Basic to an understanding of silent ischemia, its prevalence, precipitating factors, significance as a risk factor, and response to therapy, is knowledge of the effectiveness of the technologies used to detect it.Twenty-five years of developments in the theory and practice of laboratory test interpretation have con- tributed to the rational use of noninvasive tests for the diagnosis of coronary artery disease.The principles governing test interpretation so arduously derived over this time should be, but perhaps are not being, applied to the detection of myocardial ischemia as an entity unto itself.Since the implications for management in- herent in the diagnosis of ischemia may differ from those emanating from the diagnosis of coronary artery disease, tests designed to detect myocardial ischemia should be interpreted with the effectiveness of the test for that purpose in mind, and transfer of information relative to the effectiveness of the test for the diagnosis of coronary artery disease to ischemia should not be done without consideration of the appropriateness of such a transfer.The tests that are used to evaluate patients with coronary artery disease can be divided into four categories (table 1): tests that assess the electrical conse- quences of coronary artery disease, such as stress and ambulatory electrocardiography; tests that assess myocardial perfusion; tests that assess contractile function;and tests that assess metabolic function.These tests
Racial Differences in Cardiac Procedure Use
Authors: David Hudgins
Journal: JAMA (1994)

To the Editor.  —The article by Dr Peterson and colleagues 1 finds that despite racial differences in the use of major coronary procedures, there was no significant difference in adjusted mortality by race and class.  While I accept the point that quality of life as well as mortality needs to be taken into account, 2 another point needs careful consideration: namely, that we may be spending billions of dollars on coronary procedures for very little benefit. Perhaps this money could be better spent elsewhere on more cost-effective health measures.
Predictors of end stage lung disease in a cohort of patients with scleroderma
Authors: C Morgan
Journal: Annals of the Rheumatic Diseases (2003)

To estimate the incidence of severe lung disease in patients with scleroderma and identify the combination(s) of features present at first assessment which would be useful to predict future risk of severe lung disease.Data were analysed on 561 patients with disease onset occurring on or after 1 January 1982 and disease duration of less than five years before the first assessment. Detailed clinical and laboratory assessments were undertaken at the initial visit. End stage lung disease was defined as pulmonary hypertension requiring continuous ambulatory iloprost, or pulmonary fibrosis requiring continuous oxygen, or death from a scleroderma related lung disease. Patient status was determined at 31 December 1997. The best subset of predictors was identified by Cox regression analysis.In all, 24 patients reached end stage lung disease. The cumulative incidences were 4%, 6%, and 12% at five, seven, and 14 years respectively. As expected, the lung function tests at baseline, including being in the lowest third of either diffusing lung capacity (hazard ratio (HR) = 18.2, 95% confidence interval (CI) 3.5 to 93.8) or of forced vital capacity (HR=4.1, 95% CI 1.1 to 15.2), were highly significant predictors of end stage lung disease. Interestingly, apart from the presence of proteinuria, none of the other baseline variables, including the extent of skin disease and serological markers, were predictive of severe lung disease.End stage lung disease was infrequent in this large cohort, but the cumulative incidence increased importantly with time. The risk can be predicted from baseline assessment of pulmonary function. In particular, those with normal pulmonary function at baseline are at very low risk.
Effects of Altered Heart Rate on Chloroform-Epinephrine Cardiac Arrhythmia
Authors: Robert L. Vick
Journal: Circulation Research (1966)

In chloroform-anesthetized dogs receiving epinephrine, slowing of the heart rate invariably accompanies conversion of arrhythmia to normal supraventricular rhythm by vagal stimulation, and restoring the faster heart rate reestablishes arrhythmia. Increasing the heart rate during epinephrine infusion can induce arrhythmia or increase the proportion of ventricular ectopic beats. These observations are taken to indicate that the vagal influence on ventricular arrhythmia in these conditions is indirect and mediated through the frequency of excitation entering the ventricle. It is suggested that during chloroform anesthesia an increased heart rate favors the emergence of ventricular arrhythmia when activity propagated after successively shorter intervals encounters delay or local conduction block in the Purkinje system, and re-entry excitation is made possible. It is proposed that in these conditions ventricular tachycardia is a self-sustaining arrhythmia that must maintain a critical frequency, either intrinsically or from external (supraventricular) input. The arrhythmia is susceptible to termination by vagal stimulation when atrial slowing decreases the probability of an atrial impulse entering the ventricle at a critical time.
Abstract 326: Overexpression of the carboxyl-terminus of MUC16 can accelerate the occurrence of phenotypes in p53 heterozygous mouse model.
Authors: Huasong Tian, Qin Zhou, Alexia Iasonos, Spriggs David
Journal: Cancer Research (2013)

Abstract Ovarian cancer is the fifth leading cause of cancer death in women. Cancer antigen 125 (CA125), also known as MUC16, is a high molecular weight glycoprotein overexpressed in sera of women with epithelial ovarian cancer, but not in normal epithelial ovarian tissue. As a biomarker, CA125 is widely used to screen, diagnose and monitor the epithelial ovarian cancer. To further understand the roles of MUC16 in tumorigenesis, recently, some mouse models related Muc16 and MUC16 were created. There is no phenotype for the Muc16 knockout mice (Cheon et al., PLoS ONE, 2009). We built a MUC16 carboxyl-terminus transgenic mouse (MUC16ΔC354) and found out that the transgenic mice appear to be viable, fertile, and develop normally through the more than two years of life. In order to investigate the relationship of p53 mutation and MUC16 overexpression in tumorigensis, we generated mice in which MUC16ΔC354 can be overxepressed with p53 heterozygote. Like the MUC16ΔC354 transgenic mice, the MUC16ΔC354; p53+/- mice develop normally. Both mouse strains are susceptible to spontaneous tumors, including sarcoma and lymphoma. However, comparing p53+/- mice, overexpression of MUC16ΔC354 significantly accelerates the occurrence of phenotypes in MUC16ΔC354; p53+/- mice. Out of a study population of 94 MUC16ΔC354; p53+/- mice, 22 (23.4%) developed obvious neoplasms by 18 months of age, 13 (11.9%) out of 109 for p53+/- mice (ρ &amp;lt;0.014). Tumor tissues and tumor cells carrying MUC16ΔC354 and p53+/- are transplantable. MAPK/ERK signaling pathway is upregulated in these tumors. Our findings demonstrate our hypothesis that MUC16 may play a role in tumorigensis. Citation Format: Huasong Tian, Qin Zhou, Alexia Iasonos, Spriggs David. Overexpression of the carboxyl-terminus of MUC16 can accelerate the occurrence of phenotypes in p53 heterozygous mouse model. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 326. doi:10.1158/1538-7445.AM2013-326
Switching From Natalizumab to Fingolimod in Multiple Sclerosis
Authors: Mikael Cohen, Elisabeth Maillart, Ayman Tourbah, Jérôme De Sèze, Sandra Vukusic, David Brassat, Olivier Anne, Sandrine Wiertlewski, William Camu, Sylvie Courtois, Aurélie Ruet, Marc Debouverie, Emmanuelle Le Page, Olivier Casez, Olivier Heinzlef, Bruno Stankoff, Bertrand Bourre, Giovanni Castelnovo, Audrey Rico, Eric Berger, Jean-Philippe Camdessanche, Gilles Defer, Pierre Clavelou, Abdullatif Al Khedr, Hélène Zephir, Agnès Fromont, Caroline Papeix, Bruno Brochet, Jean Pelletier, Christine Lebrun
Journal: JAMA Neurology (2014)

The safety and efficacy of switching from natalizumab to fingolimod have not yet been evaluated in a large cohort of patients with multiple sclerosis (MS) to our knowledge.To collect data from patients with MS switching from natalizumab to fingolimod.The Enquête Nationale sur l'Introduction du Fingolimod en Relais au Natalizumab (ENIGM) study, a survey-based, observational multicenter cohort study among MS tertiary referral centers. Participants were patients for whom a switch from natalizumab to fingolimod was planned. Clinical data were collected on natalizumab treatment, duration and management of the washout period (WP), and relapse or adverse events during the WP and after the initiation of fingolimod.Occurrence of MS relapse during the WP or during a 6-month follow-up period after the initiation of fingolimod.Thirty-six French MS tertiary referral centers participated. In total, 333 patients with MS switched from natalizumab to fingolimod after a mean of 31 natalizumab infusions (female to male ratio, 2.36; mean age, 41 years; and Expanded Disability Status Scale score at the initiation of natalizumab, 3.6). Seventy-one percent were seropositive for the JC polyomavirus. The Expanded Disability Status Scale score remained stable for patients receiving natalizumab. Twenty-seven percent of patients relapsed during the WP. A WP shorter than 3 months was associated with a lower risk of relapse (odds ratio, 0.23; P = .001) and with less disease activity before natalizumab initiation (P = .03). Patients who stopped natalizumab because of poor tolerance or lack of efficacy also had a higher risk of relapse (odds ratio, 3.20; P = .004). Twenty percent of patients relapsed during the first 6 months of fingolimod therapy. Three percent stopped fingolimod for efficacy, tolerance, or compliance issues. In the multivariate analysis, the occurrence of relapse during the WP was the only significant prognostic factor for relapse during fingolimod therapy (odds ratio, 3.80; P = .05).In this study, switching from natalizumab to fingolimod was associated with a risk of MS reactivation during the WP or shortly after fingolimod initiation. The WP should be shorter than 3 months.
Treatment of hypertensive emergencies with oral labetalol.
Authors: R R Ghose, Y B Mathur, M Upadhyay, W D Morgan, S Khan
Journal: BMJ (1978)

the right leg at age 52 and later of left leg.No history of DVT; no family history of leg ulcers.Left inguinal herniorrhaphy at age 45.Case 2-Born 1915, single, height 1-8 m, weight 95 3 kg.Ulceration of left leg at age 39.Mild eczema of the right leg.No history of DVT.Mother and maternal aunt had leg ulcers.Case 3-Born 1944, single, height 1 8 m, weight 93-9 kg.Ulceration of the right leg at age 29.Four years previously he injured the right foot.This was followed by DVT and pulmonary embolus.Case 4-Born 1918, married, height 1 77 m, weight 92 1 kg.At age 53 ulceration of the left leg developed and later eczema of the right leg.Thrombophlebitis of the left leg occurred before ulceration.History of varicose veins in his mother's family.Case 5-Born 1924, height 1-77 m.Ulceration of right leg at age 40.Operation for varicose veins at 27.No history of phlebitis or thrombosis.His mother had varicose veins and his maternal grandmother leg ulcers.Two brothers had no leg trouble.Case 6-Born 1907, very tall, weight 76-9 kg.Ulceration of legs present with a generalised rash at age 44.Subsequently he had eczema of both legs and a small ulcer on the medial aspect of the left ankle.
ICU Bed Supply, Utilization, and Health Care Spending
Authors: Rebecca A. Gooch, Jeremy M. Kahn
Journal: JAMA (2014)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Vascular anastomosis using controlled phase transitions in poloxamer gels
Authors: Edward I Chang, Michael G Galvez, Jason P Glotzbach, Cynthia D Hamou, Samyra El-ftesi, C Travis Rappleye, Kristin-Maria Sommer, Jayakumar Rajadas, Oscar J Abilez, Gerald G Fuller, Michael T Longaker, Geoffrey C Gurtner
Journal: Nature Medicine (2011)
A Total Occlusion, Two 70 Per Cent Lesions, and Normal Ventricular Function
Authors: Myron L. Weisfeldt
Journal: New England Journal of Medicine (1984)

How can a patient with advanced atherosclerosis, including a total coronary-artery occlusion, have normal cardiac function? The answer involves the complexities of the relation between coronary-artery anatomy and coronary physiology in ischemic heart disease. Total occlusion of a major artery with little or no detectable left ventricular injury is not an infrequent finding in patients undergoing catheterization for symptomatic disease. In such a circumstance the physiology of myocardial blood flow is a more important determinant of the fate of myocardium within the distribution of a given coronary artery than is the severity of the anatomic lesion.The paper by White . . .
Insufficient evidence for association of NOD2/CARD15 or other inflammatory bowel disease–associated markers on GVHD incidence or other adverse outcomes in T-replete, unrelated donor transplantation
Authors: Yume Nguyen, Abed Al-Lehibi, Elizabeth Gorbe, Ellen Li, Michael Haagenson, Tao Wang, Stephen Spellman, Stephanie J. Lee, Nicholas O. Davidson
Journal: Blood (2010)
VA Funding Disputed
Authors: Mike Mitka
Journal: JAMA (2006)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Italian auditor criticises contract for H1N1 vaccine
Authors: F. Turone
Journal: BMJ (2010)

The contract between the drug firm Novartis and Italy’s health ministry over the purchase of 24 million doses of the H1N1 flu vaccine Focetria raises “many perplexities,” a report from the Italian Court of Audit (Corte dei Conti) has said.

The court is an autonomous and independent judicial body charged with conducting financial and legislative audits of most public institutions, including the government.

The contract for the swine flu vaccine, worth €187m (£154m; $234m), was signed in August 2009. It was submitted for approval …
The Role of Routine Clinical Pretreatment 18F-FDG PET/CT in Predicting Outcome of Colorectal Liver Metastasis
Authors: Henry H. Tam, Gary J. Cook, Ian Chau, Brent Drake, Imene Zerizer, Yong Du, David Cunningham, Dow-Mu Koh, Sue S.C. Chua
Journal: Clinical Nuclear Medicine (2015)

Objective The aim of this study was to determine the value of SUV-based metabolic parameters derived from pretreatment 18F-FDG PET/CT of colorectal liver metastases in predicting disease response, progression-free survival (PFS), and overall survival (OS). Patients and Methods We retrospectively reviewed 70 colorectal patients with liver metastases who underwent pretreatment 18F-FDG PET/CT. SUVmean, SUVmax, TLG (total lesion glycolysis), metabolic tumor volume, and metabolic tumor diameter were the metabolic parameters derived from volume of interest analysis of the most FDG-avid liver lesion in each subject. Clinical and laboratory parameters were recorded. Tumor response was assessed by response evaluation criteria in solid tumors 1.1 criteria at 12 weeks after treatment. Associations between tumor response, metabolic parameters, and clinical/laboratory parameters were examined by 1-way analysis of variance. The relationship of the metabolic parameters with PFS and OS was determined by Kaplan-Meier analyses and further confirmed with multivariate Cox regression analyses. Results SUVmean less than 4.48, SUVmax less than 6.59, TLG less than 75.2, metabolic tumor volume less than 4.49 cm3, and hemoglobin level greater than or equal to 11 g/dL were associated with longer PFS (P < 0.05). Prior surgery or radiofrequency ablation to the liver metastases was the only additional factor shown to be associated with longer OS. Conclusions SUV-based metabolic parameters derived from pretreatment 18F-FDG PET/CT can predict PFS in colorectal liver metastases.
Basic Medical Virology
Authors: Friedrich Deinhardt
Journal: JAMA (1967)

This book was written for students; it can equally well serve the needs of the physician who wishes to learn about a subject which was in infancy during his medical school years. It gives a brief resume of some of the mechanisms underlying viral infections but most of the book comprises chapters devoted to individual groups of viruses and written mostly by basic scientists specializing in the particular groups.  The book has both the merits and the failings of any multiple-author text which reviews a rapidly expanding field. The quality of writing is uneven, there is duplication, and the weight of the information, given without emphasis, may well confuse rather than enlighten the reader. As a minor example, the excellent and comprehensive references cited and listed at the end of each chapter will be invaluable for experimental investigators but cannot avoid bewildering the student. There is insufficient discussion of basic